The Novel Arylamidine T-2307 Maintains In Vitro and In Vivo Activity against Echinocandin-Resistant Candida albicans
Open accessAbstract
We evaluated the in vitro and in vivo activities of the investigational arylamidine T-2307 against echinocandin-resistant Candida albicans . T-2307 demonstrated potent in vitro activity, and daily subcutaneous doses between 0.75 and 6 mg/kg of body weight significantly improved survival and reduced fungal burden compared to placebo control and caspofungin (10 mg/kg/day) in mice with invasive candidiasis caused by an echinocandin-resistant strain. Thus, T-2307 may have potential use in the treatment of echinocandin-resistant C. albicans infections.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
T-2307 is effective against drug-resistant fungal isolates both in vitro and in vivo, including echinocandin-resistant C. albicans and Candida glabrata and azole-resistant C. albicans.
“Moreover, T-2307 is effective against drug-resistant fungal isolates both in vitro and in vivo, which highlights its potent antifungal activities against echinocandin-resistant C. albicans and Candida glabrata and azole-resistant C. albicans (29, 32–34).”
From Recent Progress in Research on Mitochondrion-Targeted Antifungal Drugs: a Review (2023) · cites this paper as [32]
Cites
Epidemiology and risk factors for invasive candidiasis
Yapar, N. (2014) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s40160 · Cited by 610 · see citing works
Epidemiology of candidaemia and invasive candidiasis. A changing face
Quindós, G. (2014) · Revista Iberoamericana de Micología · doi:10.1016/j.riam.2013.10.001 · Cited by 219 · see citing works
T-2307 Causes Collapse of Mitochondrial Membrane Potential in Yeast
Shibata, T., Takahashi, T., Yamada, E., Kimura, A., Nishikawa, H., Hayakawa, H., Nomura, N., & Mitsuyama, J. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.05954-11 · Cited by 99 · see citing works
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
The antifungal arsenal: alternative drugs and future targets
Wiederhold, N. P. (2018) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2017.09.002 · Cited by 149 · see citing works
Self-citationDevelopment and research progress of anti-drug resistant fungal drugs
Cui, X., Wang, L., Lü, Y., & Yue, C. (2022) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2022.08.004 · Cited by 85 · see citing works
Yamashita, K., Miyazaki, T., Fukuda, Y., Mitsuyama, J., Saijo, T., Shimamura, S., Yamamoto, K., Imamura, Y., Izumikawa, K., Yanagihara, K., et al. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00374-19 · Cited by 77 · see citing works
Self-citationWiederhold, N. P., Najvar, L. K., Jaramillo, R., Olivo, M., Patterson, H., Connell, A., Fukuda, Y., Mitsuyama, J., Catano, G., & Patterson, T. F. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02198-19 · Cited by 50 · see citing works
Self-citationRecent Progress in Research on Mitochondrion-Targeted Antifungal Drugs: a Review
Qin, Y., Wang, J., Lv, Q., & Han, B. (2023) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00003-23 · Cited by 38 · see citing works
Wiederhold, N. P. (2021) · Journal of Fungi · doi:10.3390/jof7020130 · Cited by 37 · see citing works
Self-citation
- Authors
- Wiederhold, N. P., Najvar, L. K., Fothergill, A. W., Bocanegra, R., Olivo, M., McCarthy, D. I., Kirkpatrick, W. R., Fukuda, Y., Mitsuyama, J., & Patterson, T. F.
- Affiliations
- The University of Texas at San Antonio Health Science Center (US)
- Toyama Chemical Co., Ltd., Toyama, Japan
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2015-02
- Volume
- 59
- Issue
- 2
- Pages
- 1341-1343
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- PMC
- PMC4335842
- OpenAlex
- W2084496560
- Cited by
- 36
- References
- 3
- Citations by year
- 2026: 1 · 2025: 4 · 2024: 4 · 2023: 3 · 2022: 3 · 2021: 5 · 2020: 2 · 2019: 3 · 2018: 3 · 2017: 2 · 2016: 2 · 2015: 4
- FWCI
- 1.87
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Antimicrobial Agents and Chemotherapy (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Allergy and Infectious Diseases (HHSN272201000038I, HHSN272201000038C)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Life Sciences › Agricultural and Biological Sciences › Ecology, Evolution, Behavior and Systematics › Fungal Plant Pathogen Control
- Health Sciences › Medicine › Epidemiology › Fungal Infections and Studies
- Keywords
- Candida albicans, echinocandin resistance, invasive candidiasis, antifungal activity, caspofungin, fungal burden
- MeSH terms
- Amidines, Animals, Antifungal Agents, Candida albicans, Candidiasis, Male, Mice, Inbred ICR, Microbial Sensitivity Tests, Drug Resistance, Fungal, Mice, Echinocandins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
